Okyo Pharma Limited ADR (OKYO) Stock Price, Quote & News

Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acu...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: okyopharma.com

Address:

14/15 Conduit St, Floor 4, London, United Kingdom

Orlandotrader May. 31 at 5:36 PM

$OKYO Get your Cheepies Soon!!! These prices will not Last.

0 · Reply

Orlandotrader May. 23 at 8:08 PM

$OKYO Potential near-term catalysts for investors include completion of protocol finalisation, site identification and study activation activities. Dempsey said the company expects to achieve first patient first visit milestones within the next three to six months as the clinical program progresses.

0 · Reply

Orlandotrader May. 23 at 8:05 PM

$OKYO CEO Robert Dempsey said Sacchetti’s combination of clinical, academic and industry expertise would strengthen the company’s position as it progresses its clinical plans in the United States and Europe. Dempsey described neuropathic corneal pain as a “severe, debilitating condition” that remains significantly under researched and currently has no FDA-approved treatment options. He said OKYO Pharma is seeking to pioneer a new ocular therapeutic category through its lead candidate Urcosimod.

0 · Reply

Orlandotrader May. 22 at 12:25 PM

$OKYO Lots of Talent but we need to start Recruiting for this Six month Trial.

0 · Reply

Orlandotrader May. 20 at 8:11 PM

$OKYO OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board Sacchetti is an associate professor of ophthalmology at Link University in Rome. According to the company, she brings extensive clinical, research, and industry experience in cornea and ocular surface diseases, including prior leadership as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici. OKYO noted that Sacchetti’s experience in targeted nerve regeneration, pain signaling modulation, and advanced diagnostics will support its development efforts in neuro-inflammatory eye disease.

0 · Reply

Orlandotrader May. 20 at 8:09 PM

$OKYO OKYO Pharma Limited Sponsored ADR (OKYO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

0 · Reply

Orlandotrader May. 6 at 7:47 PM

$OKYO Knock down that Wall Mr Gorbachev. Need news update to take out that 1.70 level. Let’s Start this Sux Month Trial Already. Stop with the Worthless Presentations.

0 · Reply

Orlandotrader May. 5 at 12:59 PM

$OKYO Should be getting Updates on New Trial Recruitment soon as they are Targeting Mid Year Start.

0 · Reply

BillionerOfKing May. 1 at 10:42 PM

$OKYO Current Stock Price: $1.65

0 · Reply

jpurr Apr. 28 at 8:58 PM

$OKYO The Gabe factor at play here?

1 · Reply

OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD

Apr 29, 2026, 7:00 AM EDT - 5 weeks ago

OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

Apr 7, 2026, 7:00 AM EDT - 2 months ago

OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

Mar 19, 2026, 12:00 PM EDT - 2 months ago

OKYO Pharma Announces Chairman and Founder Acquires Shares

2026-03-19T14:15:16.000Z - 2 months ago

Okyo Pharma director John Brancaccio acquires 5,000 shares

Mar 19, 2026, 10:00 AM EDT - 2 months ago

OKYO Pharma Announces Director Acquires Shares

2026-03-19T11:37:09.000Z - 2 months ago

Okyo Pharma CDO, director acquire shares

Mar 19, 2026, 7:00 AM EDT - 2 months ago

OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

2026-03-18T11:22:52.000Z - 2 months ago

Okyo Pharma reports results from Phase 2a trial of urcosimod

Mar 18, 2026, 7:00 AM EDT - 2 months ago

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

Feb 23, 2026, 11:00 AM EST - 3 months ago

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

2026-02-20T10:12:28.000Z - 3 months ago

Okyo Pharma initiated with an Overweight at Piper Sandler

Feb 12, 2026, 10:20 PM EST - 4 months ago

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

2026-02-12T22:20:33.000Z - 4 months ago

Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90

2026-02-12T21:06:40.000Z - 4 months ago

Okyo Pharma announces ordinary shares offering, no amount given

Feb 12, 2026, 4:01 PM EST - 4 months ago

OKYO Pharma Announces Public Offering of Ordinary Shares

Feb 11, 2026, 10:09 AM EST - 4 months ago

OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

2026-02-10T13:16:08.000Z - 4 months ago

Okyo Pharma appoints Mantelli as Chief Medical Officer

Feb 10, 2026, 8:00 AM EST - 4 months ago

OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

Jan 30, 2026, 11:30 AM EST - 4 months ago

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

2026-01-28T12:45:43.000Z - 4 months ago

Okyo Pharma announces highlights from Type C meeting with FDA on urcosimod

Jan 28, 2026, 7:40 AM EST - 4 months ago

OKYO Pharma Announces Successful Type C Meeting with the FDA

2026-01-23T12:11:12.000Z - 4 months ago

Okyo announces FDA authorized single-patient expanded IND for urcosimod

Jan 23, 2026, 7:00 AM EST - 4 months ago

FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

2026-01-05T12:21:22.000Z - 5 months ago

Okyo Pharma appoints Robery Dempsey as CEO

Dec 19, 2025, 7:00 AM EST - 5 months ago

OKYO Pharma to Ring the Opening Bell at Nasdaq

2025-12-15T13:35:29.000Z - 6 months ago

Okyo Pharma chairman acquires 24,551 company shares

2025-12-11T13:41:22.000Z - 6 months ago

Okyo Pharma’s urcosimod shows favorable corneal nerve outcomes in Phase 2 trial

2025-12-08T11:05:40.000Z - 6 months ago

Okyo Pharma initiated with a Buy at B. Riley

2025-12-03T12:05:51.000Z - 6 months ago

Okyo Pharma chairman acquires 27,051 company shares

2025-11-21T13:36:19.000Z - 6 months ago

Okyo Pharma chairman acquires 82,018 company shares

Nov 18, 2025, 8:30 AM EST - 7 months ago

OKYO Pharma to Present at OIS XV in San Diego

2025-10-16T12:35:39.000Z - 8 months ago

Okyo Pharma chairman acquires 210,000 company shares

2025-09-22T12:40:25.000Z - 9 months ago

Okyo Pharma announces plans for next stage of development for urcosimod

Sep 22, 2025, 8:30 AM EDT - 9 months ago

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

2025-07-31T10:26:14.000Z - 11 months ago

Okyo Pharma initiated with a Buy at Lucid Capital

2025-07-17T13:16:10.000Z - 11 months ago

Okyo Pharma receives $1.9M in non-dilutive funding

2025-07-16T13:25:17.000Z - 11 months ago

Okyo Pharma reports Phase 2 clinical trial results for urcosimod

Jul 16, 2025, 9:21 AM EDT - 11 months ago

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Jun 11, 2025, 10:05 AM EDT - 1 year ago

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

May 19, 2025, 7:00 AM EDT - 1 year ago

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

Apr 30, 2025, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

Mar 31, 2025, 8:00 AM EDT - 1 year ago

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Jan 31, 2025, 7:00 AM EST - 1 year ago

OKYO Pharma Announces Chairman and CEO Acquire Shares

Jan 30, 2025, 9:45 AM EST - 1 year ago

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

Nov 15, 2024, 9:00 AM EST - 1 year ago

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MUSQ

Oct 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SMXT

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma CEO Interview to Air on Bloomberg TV

Aug 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Chairman Acquires Shares

Aug 15, 2024, 12:13 PM EDT - 1 year ago

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 6, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

Jul 11, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

Jul 10, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Apr 30, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

Apr 8, 2024, 7:00 PM EDT - 2 years ago

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

$OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery$

Apr 2, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Mar 22, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Mar 21, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Mar 20, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

Feb 9, 2024, 7:00 AM EST - 2 years ago

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

Jan 5, 2024, 9:30 AM EST - 2 years ago

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Oct 9, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

Sep 15, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 14, 2023, 9:15 AM EDT - 2 years ago

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 14, 2023, 8:45 AM EDT - 2 years ago

OKYO Pharma Limited Announces Withdrawal of Public Offering

Sep 8, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

Aug 30, 2023, 7:00 AM EDT - 3 years ago

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

Aug 15, 2023, 9:00 AM EDT - 3 years ago

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

Jul 28, 2023, 5:25 PM EDT - 3 years ago

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

Orlandotrader May. 31 at 5:36 PM

$OKYO Get your Cheepies Soon!!! These prices will not Last.

0 · Reply

Orlandotrader May. 23 at 8:08 PM

0 · Reply

Orlandotrader May. 23 at 8:05 PM

0 · Reply

Orlandotrader May. 22 at 12:25 PM

$OKYO Lots of Talent but we need to start Recruiting for this Six month Trial.

0 · Reply

Orlandotrader May. 20 at 8:11 PM

0 · Reply

Orlandotrader May. 20 at 8:09 PM

0 · Reply

Orlandotrader May. 6 at 7:47 PM

$OKYO Knock down that Wall Mr Gorbachev. Need news update to take out that 1.70 level. Let’s Start this Sux Month Trial Already. Stop with the Worthless Presentations.

0 · Reply

Orlandotrader May. 5 at 12:59 PM

$OKYO Should be getting Updates on New Trial Recruitment soon as they are Targeting Mid Year Start.

0 · Reply

BillionerOfKing May. 1 at 10:42 PM

$OKYO Current Stock Price: $1.65

0 · Reply

jpurr Apr. 28 at 8:58 PM

$OKYO The Gabe factor at play here?

1 · Reply

Orlandotrader Apr. 22 at 3:34 PM

$OKYO Hello management any one home?

0 · Reply

Oscarca Apr. 13 at 9:45 AM

$OKYO What are you guys thinking, PRs this week or not ?

1 · Reply

Oscarca Apr. 10 at 1:34 PM

$OKYO Hoping for some PRs next week after the ASCRS presentation tomorrow 🙏🏼

1 · Reply

focafoca99 Apr. 7 at 9:10 PM

$OKYO will hold a scientific advisory board meeting during ASCRS and present urcosimod data there.

0 · Reply

Oscarca Apr. 1 at 8:48 AM

$OKYO It is confirmed that the trials will start in June but no news on where and how to apply yet. Would assume this phase 2b/3 study would pop up on http://clinicaltrials.gov at anytime now..

0 · Reply

Oscarca Mar. 31 at 8:15 AM

$OKYO Robert J. Dempsey the new ceo commercialized two of the biggest blockbuster eye drops ”Restasis” and ”Xiidra” both which has reached over a billion dollars in annually revenue. Then you have the new Chief Medical Officer Flavio Mantelli who commercialized the eye drop medication ”Oxervate” which also generates close to a billon dollars. The team/roster/squad that OKYO has is just insanely strong and insiders owning 32% of the company where as the founder owns 29% which is quite high for a small biotech company.

1 · Reply

aletz Mar. 30 at 10:12 AM

$OKYO https://www.biostockinfo.com/biotech-catalyst-ai-scanner-april-wk1/

1 · Reply

Oscarca Mar. 24 at 9:07 PM

$OKYO one of the brains behind urcosimod Pedram Hamrah being named in the top 50 list for most influential ophthalmologist in the world.

0 · Reply

Oscarca Mar. 24 at 1:27 PM

$OKYO patiently waiting for phase 2b/3 study enrollment news. If they are starting trials in June it feels like news should come out at any given time about facilities, locations, enrollment number, criteria’s etc.

2 · Reply

Orlandotrader Mar. 19 at 2:32 PM

$OKYO John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company’s ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares.

0 · Reply

DARKP00L Mar. 19 at 2:23 PM

$OKYO 10:06 on Mar. 19 2026 OKYO Pharma Director John Brancaccio Buys 5,000 Shares At An Average Price Of $1.61, Raising Total Holdings to 31,201 #tradeideas

0 · Reply

DARKP00L Mar. 19 at 11:20 AM

$OKYO 07:13 on Mar. 19 2026 OKYO Pharma Executive Buys More Shares, Signals Confidence #tradeideas

0 · Reply

Market Cap	67.32M
Revenue (ttm)	0.00
Net Income (ttm)	-4.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.06

Volume	58,500
Avg Vol	68,486
Day's Range	N/A - N/A
Shares Out	40.56M
Stochastic %K	56%
Beta	0.02
Analysts	Strong Sell
Price Target	$8.00